Mania News and Research

RSS

People who suffer from severe depression have more nerve cells in the part of the brain that controls emotion

Studies of postmortem brains of patients diagnosed with major depressive disorder (MDD) showed a 31 percent greater than average number of nerve cells in the portion of the thalamus involved with emotional regulation.

2 Jul 2004

Drink that enhances the effectiveness of medication given to treat psychiatric illnesses

Scientists funded by the UK's largest biomedical research charity, The Wellcome Trust, have developed a drink that enhances the effectiveness of medication given to treat psychiatric illnesses such as mania and schizophrenia.

10 Jun 2004

Bipolar disorder, one of the illnesses that will be studied and treated at the new Mood Disorders Centre of Excellence

Imagine suffering frequent, extreme and disabling mood swings that won’t go away despite years of different treatments and diagnoses.

26 May 2004

Public Health Advisory for medical professionals with patients on anti-depression medication

On Monday, March 22, 2004 the Food and Drug Administration issued a Public Health Advisory for medical professionals to monitor for signs of suicidal ideation in individuals who have recently started taking anti-depression medication or have had a recent change in dosage, especially for children who are taking these medications. Antidepressant medications involved in this warning include: Prozac (Fluoxetine), Zoloft, Paxil, Luvox, Celexa, Lexapro, Wellbutrin, Effexor,, Serzone, and Remeron.

25 Apr 2004

The Food and Drug Administration issues warning on antidepressants

The Food and Drug Administration (FDA) is issuing a warning about the possibility of worsening depression or suicidal thought in people, particularly children, who take any of 10 popular antidepressants, especially at the beginning of treatment or when the dosage is changed.

6 Apr 2004

FDA has approved Zyprexa, injectable anti-psychotic drug

Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.

30 Mar 2004